Articles

Do High Drug Prices Drive Innovation, Or Hurt It?

In a Forbes guest post, Dr. Bach responds to Dr. John LaMattina's criticism of a previous post authored by Dr. Bach.
Originally published on 11/03/2014 in Forbes: Debate

Dr. Bach responds with two primary points:

1) The argument Dr. LaMattina presents is chosen from a pick-list of rationales for high pricing because it loosely fits the scenario.

2) The post hoc rationale for Gilead's pricing undercuts a core principle related to the value of innovation that is not transferred back to the innovators but instead goes to society.

Read the full article here.

Share

Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

R&D Costs Do Not Explain Elevated U.S. Drug Prices
Drug prices in other high income countries for the 20 top selling drugs globally make up less than half of U.S. net drug prices.
HA Blog 03/07/2017
Do High Drug Prices Drive Innovation, Or Hurt It?
In a Forbes guest post, Dr. Bach responds to Dr. John LaMattina's criticism of a previous post authored by Dr. Bach.
Forbes: Debate 11/03/2014
Could High Drug Prices Be Bad for Innovation?
Industry leaders argue that high prices are necessary for innovation, but just how high do prices need to be?
Forbes: Cancer 10/23/2014
Xeljanz, the FDA, and nine years of patient harm
Quantifying population-level adverse events in the near decade between when safety concerns were identified and FDA action
Drug Pricing Lab 05/31/2022
Atypical antipsychotics: Decades of use, unfathomable harms
Using attributable risk calculations to quantify how many premature deaths resulted from atypical antipsychotic use in the elderly
Drug Pricing Lab 05/31/2022
Medicare Part B Premium Dynamics Explained
The Drug Pricing Lab commissioned Milliman to prepare a report exploring the impact of changes in Medicare Part B program costs on beneficiaries’ premiums and Social Security payments. This report focuses on the 2022 Part B premium for beneficiaries with various income levels to illustrate the payment dynamics and discusses the implications for related programs.
Milliman 12/23/2021
Comparing Factors that Influence Pharmaceutical Pricing and Access in the…
Drug prices in the United States are some of the highest in the world, which has triggered several policy proposals aimed at adopting pricing strategies used by other countries.
Drug Pricing Lab 12/20/2021
Biosimilars in Medicare Part D: pricing dynamics and considerations
The Drug Pricing Lab engaged Milliman to prepare a report summarizing the pricing dynamics affecting utilization of biosimilars in the current Medicare Part D marketplace and under the proposed Part D benefit design in the Build Back Better Act.

This report was commissioned by the Drug Pricing Lab.
Milliman 12/14/2021
Evaluating Industry’s Drug Pricing Claims
A closer look at three of PhRMA’s most cited talking points.
Drug Pricing Lab 11/18/2021
Mapping conflict of interests: scoping review
A scoping review of the literature to identify all known ties between the medical product industry and the parties and activities in the healthcare ecosystem.
Drug Pricing Lab 11/03/2021
Production Plus Profit Pricing (P-quad) FAQ
08/17/2021
What A Waste! The National Academy Of Medicine’s Report On…
Why Congress should not follow the National Academy of Science, Engineering, and Medicine’s recommendation to remove the JW modifier.
Health Affairs Blog 07/09/2021
Newsletter

Stay up to date on our work and news